Company intelligence / Profile preview

Petros Pharmaceuticals, Inc.

New York, New York, United Statespetrospharma.com ↗

Ownership: Public · PTPI
Employees: ~18
Development stage: Commercial

Overview

Petros Pharmaceuticals has commercial products for men's health including Stendra (avanafil) for erectile dysfunction. They are also developing H-100, a topical treatment for Peyronie's disease currently in Phase I. Their strategic focus has shifted toward developing a SaaS platform to facilitate prescription-to-OTC switches under FDA's ACNU guidelines.

Therapeutic areas: Men's Health
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

H100

Partnerships

Hims & Hers Health, Inc.

Financials

Market cap: $245.8K
Total revenue: $0
Enterprise value: $-3.2M

Beyond the preview

Go deeper on Petros Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Petros Pharmaceuticals, Inc..

Explore the full profile